Walvax Biotechnology Co., Ltd.
Walvax Biotechnology Co., Ltd.
Aktie · CNE100000WN2 (XSHE)
Übersicht
Kein Kurs
Schlusskurs XSHE 27.10.2025: 11,34 CNY
27.10.2025 07:04
Aktuelle Kurse von Walvax Biotechnology Co., Ltd.
BörseTickerWährungLetzter UmsatzKursTagesveränderung
XSHE: SHENZHEN STOCK EXCHANGE
SHENZHEN STOCK EXCHANGE
300142.SZ
CNY
27.10.2025 07:04
11,34 CNY
-0,010 CNY
-0,09 %
Free Float & Liquidität
Free Float 89,99 %
Shares Float 1,43 B
Ausstehende Aktien 1,59 B
Investierte Fonds

Folgende Fonds haben in Walvax Biotechnology Co., Ltd. investiert:

Fonds
iShares MSCI China UCITS ETF USD (Dist)
Vol. in Mio
1,14
Anteil (%)
0,03 %
Fonds
iShares MSCI EM IMI ESG Screened UCITS ETF USD (Acc)
Vol. in Mio
275,07
Anteil (%)
0,02 %
Fonds
iShares MSCI EM IMI ESG Screened UCITS ETF USD (Dist)
Vol. in Mio
54,34
Anteil (%)
0,02 %
Fonds
iShares MSCI EM ESG Enhanced UCITS ETF USD (Dist)
Vol. in Mio
18,49
Anteil (%)
0,0069 %
Fonds
iShares MSCI EM ESG Enhanced UCITS ETF USD (Acc)
Vol. in Mio
77,88
Anteil (%)
0,0069 %
Firmenprofil zu Walvax Biotechnology Co., Ltd. Aktie
Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, researches and develops, produces, and sells bio-medicine products in China. The company offers biomedicines, such as vaccines, blood products, and others. It provides Group A, C meningococcal polysaccharide conjugate vaccine for infants below or equal to 2 years preventing diseases, such as cerebrospinal meningitis and septicemia; Group A and C meningococcal polysaccharide vaccine for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium Neisseria meningitidis group A or group C; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis group A, C, Y, and W135. The company also offers haemophilus influenzae type b conjugate vaccine for children from the age of 2 months to 5 years for the prevention of infectious diseases, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, etc. In addition, it provides diphtheria, tetanus, and acellular pertussis combined vaccine for the prevention of diphtheria, tetanus, and pertussis for individuals from the age of 3 months to 6 years; and 23-valent pneumococcal polysaccharide vaccine for children above 2 years old to prevent pneumococcal disease caused by 23 serotypes. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.
Erhalte tagesaktuelle Insights vom finAgent über Walvax Biotechnology Co., Ltd.

Unternehmensdaten

Name Walvax Biotechnology Co., Ltd.
Firma Walvax Biotechnology Co., Ltd.
Website https://www.walvax.com
Heimatbörse XSHE SHENZHEN STOCK EXCHANGE
ISIN CNE100000WN2
Wertpapierart Aktie
Sektor Healthcare
Branche Drug Manufacturers - Specialty & Generic
CEO Wei Yao
Marktkapitalisierung 20 Mrd.
Land China
Währung CNY
Mitarbeiter 2,4 T
Adresse Building 9A, 19th Floor, 650106 Kunming
IPO Datum 2010-11-12

Ticker Symbole

Name Symbol
SHENZHEN STOCK EXCHANGE 300142.SZ
Weitere Aktien
Investoren, die Walvax Biotechnology Co., Ltd. halten, haben auch folgende Aktien im Depot:
CABEI 22/26 MTN
CABEI 22/26 MTN Anleihe
CORP.ANDINA 25/30
CORP.ANDINA 25/30 Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025